Iconovo AB stock analysis
Want to see SE:ICO full AI Analyst Report?
Iconovo AB (ICO) Stock Price & Analysis
ICO Stock Chart & Stats
- Day’s Range
- SEK 1.05 - SEK 1.10
- 52-Week Range
- SEK 0.87 - SEK 1.65
- Previous Close
- SEK 1.04
- Volume
- N/A
- Average Volume (3M)
- 66.17K
- Market Cap
- SEK 100.50M
- Enterprise Value
- SEK 94.93M
- Total Cash (Recent Filing)
- SEK 26.34M
- Total Debt (Recent Filing)
- SEK 3.46M
- Price to Earnings (P/E)
- ―
- Beta
- -0.44
- Next Earnings
- Feb 26, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
Strong revenue growth indicates expanding commercial activity and increasing adoption of Iconovo’s offerings. If sustained, this growth can improve operating leverage, broaden the partner base, and create a larger revenue base from which the company may eventually build more durable earnings.
Low Leverage
Very low leverage limits interest and refinancing pressure, preserving financial flexibility while Iconovo invests in development and commercialization. A sizable equity base also provides greater capacity to absorb operating volatility than a highly debt-funded structure, although losses remain a constraint.
Proprietary Inhalation Platform
A portfolio of proprietary inhaler platforms, combined with formulation, device integration and development services, gives Iconovo multiple ways to support partner programs. This model can make its technology relevant across generic, value-added and other inhaled therapies over time.
Bears Say
Deep Unprofitability
Negative gross profit and exceptionally large losses show that current revenue is not translating into sustainable economics. Until pricing, product mix or cost absorption improves, additional sales may not generate proportional earnings, keeping profitability and the path to self-funding uncertain.
Persistent Cash Burn
Sustained negative operating and free cash flow means the business continues to consume cash rather than fund itself. Ongoing burn can restrict investment choices and create continued funding needs, while the lack of stabilization increases the importance of achieving commercial and margin improvement.
Margin Volatility
The reversal from positive gross profit to sharply negative results suggests that margins are not yet durable at the company’s current scale. Combined with materially negative returns on equity, this weak earnings quality could increase pressure for future equity funding if profitability does not improve.
ICO FAQ
What was Iconovo AB’s price range in the past 12 months?
What is Iconovo AB’s market cap?
When is Iconovo AB’s upcoming earnings report date?
How were Iconovo AB’s earnings last quarter?
Is Iconovo AB overvalued?
Does Iconovo AB pay dividends?
What is Iconovo AB’s EPS estimate?
How many shares outstanding does Iconovo AB have?
What happened to Iconovo AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Iconovo AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Iconovo AB
Based in Lund, Sweden, Iconovo AB (publ) focuses on the creation and licensing of advanced inhalation delivery systems. Their product portfolio encompasses a variety of dry powder inhalers, such as the versatile multi-dose ICOres, the capsule-driven ICOcap, the single-use disposable ICOone, and the pre-metered ICOpre. Beyond these standard devices, the company also designs custom inhalation solutions, primarily catering to generic pharmaceutical firms. Iconovo is involved in significant collaborative ventures, including a project with Immune System Regulation AB to develop an inhaled COVID-19 vaccine using their ICOone inhaler, and a partnership with Respiratorius AB (publ) to formulate an inhalation treatment for COPD. The company was established in 2013.
- Sector
- General
- Industry
- Medical - Devices
- CEO
- Anders Mansson
- Employees
- 12
- Website
- www.iconovo.se
- Address
- Ideongatan 3 A-B, Lund, SN, 223 70, SE
Iconovo AB (ICO) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 6 | 14 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 0 | 0 | 12 |

